| Dr Kevin Boyd Collen, MD | |
|
1201 Liberty Pike Ste 205, Franklin, TN 37067-5646 | |
| (615) 637-1532 | |
| (888) 531-4168 |
| Full Name | Dr Kevin Boyd Collen |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 25 Years |
| Location | 1201 Liberty Pike Ste 205, Franklin, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235153446 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | MD0000038029 (Tennessee) | Primary |
| Entity Name | Fast Pace Medical Clinic Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134452865 PECOS PAC ID: 5395881841 Enrollment ID: O20091014000112 |
News Archive
Experts are recommending that a malaria vaccine progress to Phase 3 trials following the successful trial of the RTS, S/AS01E malaria vaccine among 5-17 month old children in Korogwe, Tanzania and coastal Kenya, which is reported in the New England Journal of Medicine (NEJM).
"The U.K. will hold an international food security summit during the Olympic games in London this summer, British Prime Minister David Cameron has announced in a statement to the House of Commons," AlertNet reports.
Eisai announced today that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound perampanel (E2007) based on the results of three Phase III pivotal studies. Perampanel is a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of partial onset seizures in patients with epilepsy.
Immigrants from countries with high rates of tuberculosis who move to countries of low TB incidence do not pose a public health threat to native citizens, according to researchers in Norway, who analyzed the incidence and genetic origins of all known cases of TB in the country between 1993 and 2005.
› Verified 8 days ago
| Entity Name | Kevin B. Collen, M.d. Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326306374 PECOS PAC ID: 4880859412 Enrollment ID: O20120706000020 |
News Archive
Experts are recommending that a malaria vaccine progress to Phase 3 trials following the successful trial of the RTS, S/AS01E malaria vaccine among 5-17 month old children in Korogwe, Tanzania and coastal Kenya, which is reported in the New England Journal of Medicine (NEJM).
"The U.K. will hold an international food security summit during the Olympic games in London this summer, British Prime Minister David Cameron has announced in a statement to the House of Commons," AlertNet reports.
Eisai announced today that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound perampanel (E2007) based on the results of three Phase III pivotal studies. Perampanel is a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of partial onset seizures in patients with epilepsy.
Immigrants from countries with high rates of tuberculosis who move to countries of low TB incidence do not pose a public health threat to native citizens, according to researchers in Norway, who analyzed the incidence and genetic origins of all known cases of TB in the country between 1993 and 2005.
› Verified 8 days ago
| Entity Name | Ipc Pac Healthcare Services Of Tennessee Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104277656 PECOS PAC ID: 0840587572 Enrollment ID: O20160928000541 |
News Archive
Experts are recommending that a malaria vaccine progress to Phase 3 trials following the successful trial of the RTS, S/AS01E malaria vaccine among 5-17 month old children in Korogwe, Tanzania and coastal Kenya, which is reported in the New England Journal of Medicine (NEJM).
"The U.K. will hold an international food security summit during the Olympic games in London this summer, British Prime Minister David Cameron has announced in a statement to the House of Commons," AlertNet reports.
Eisai announced today that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound perampanel (E2007) based on the results of three Phase III pivotal studies. Perampanel is a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of partial onset seizures in patients with epilepsy.
Immigrants from countries with high rates of tuberculosis who move to countries of low TB incidence do not pose a public health threat to native citizens, according to researchers in Norway, who analyzed the incidence and genetic origins of all known cases of TB in the country between 1993 and 2005.
› Verified 8 days ago
| Entity Name | Nv Pacs 2 Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427534809 PECOS PAC ID: 0941550578 Enrollment ID: O20210903001263 |
News Archive
Experts are recommending that a malaria vaccine progress to Phase 3 trials following the successful trial of the RTS, S/AS01E malaria vaccine among 5-17 month old children in Korogwe, Tanzania and coastal Kenya, which is reported in the New England Journal of Medicine (NEJM).
"The U.K. will hold an international food security summit during the Olympic games in London this summer, British Prime Minister David Cameron has announced in a statement to the House of Commons," AlertNet reports.
Eisai announced today that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound perampanel (E2007) based on the results of three Phase III pivotal studies. Perampanel is a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of partial onset seizures in patients with epilepsy.
Immigrants from countries with high rates of tuberculosis who move to countries of low TB incidence do not pose a public health threat to native citizens, according to researchers in Norway, who analyzed the incidence and genetic origins of all known cases of TB in the country between 1993 and 2005.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kevin Boyd Collen, MD 2809 Acklen Ave, Nashville, TN 37212-3311 Ph: (615) 969-9680 | Dr Kevin Boyd Collen, MD 1201 Liberty Pike Ste 205, Franklin, TN 37067-5646 Ph: (615) 637-1532 |
News Archive
Experts are recommending that a malaria vaccine progress to Phase 3 trials following the successful trial of the RTS, S/AS01E malaria vaccine among 5-17 month old children in Korogwe, Tanzania and coastal Kenya, which is reported in the New England Journal of Medicine (NEJM).
"The U.K. will hold an international food security summit during the Olympic games in London this summer, British Prime Minister David Cameron has announced in a statement to the House of Commons," AlertNet reports.
Eisai announced today that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound perampanel (E2007) based on the results of three Phase III pivotal studies. Perampanel is a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of partial onset seizures in patients with epilepsy.
Immigrants from countries with high rates of tuberculosis who move to countries of low TB incidence do not pose a public health threat to native citizens, according to researchers in Norway, who analyzed the incidence and genetic origins of all known cases of TB in the country between 1993 and 2005.
› Verified 8 days ago
John Lee Shuster Jr., M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 405 Duke Dr, Suite 210, Franklin, TN 37067 Phone: 844-291-4535 | |
Dr. Robert A Jack, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2010 Quail Hollow Cir, Franklin, TN 37067 Phone: 615-807-4020 Fax: 615-807-4022 | |
Ana Maria Sarasti, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 300 Stanley Park Ln, Franklin, TN 37069 Phone: 615-319-0645 Fax: 615-591-4860 | |
Mackenzie Elise Grimes, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1909 Mallory Ln Ste 200, Franklin, TN 37067 Phone: 615-771-1100 Fax: 615-771-1109 | |
Dr. Michael Jude Ferri, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2010 Quail Hollow Cir, Franklin, TN 37067 Phone: 615-807-4032 | |
Dr. James R Hart, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2014 Quail Hollow Cir, Franklin, TN 37067 Phone: 615-807-4020 Fax: 615-807-4022 | |
Gretchen H Campbell, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 4323 Carothers Pkwy, Suite 609, Franklin, TN 37067 Phone: 615-550-1800 Fax: 615-550-1801 |